

Institutional Biosafety Committee

July 10, 2026

12:00PM – 1:10PM

Teleconference

Minutes

Voting Members Present: Ami A. Patel, Elizabeth Bramhall, Jennifer Johnson, John O'Neill, Irina Luzina, Janna Barcelo, Matthew Frieman, Robert Ernst, Ciaran Skerry, Matthew Fischer

Voting Members Absent: Brian Taylor, Marianne Cloeren, Karen Scanlon, Alan Schmaljohn, Ron McNeil, Melissa Morland, Anthony Kim, Joseph Gillespie, Sammy Almashat, Sherry Bohn, Jessie Duggan, Alfredo Garzino-Demo

Other Person(s) Present: No other persons were present at the meeting

Staff Present: Matthew Fischer, John O'Neill, Holda Ramos

1 Vote on Last Meeting's Minutes

Institutional Biosafety Committee meeting on 6/5/2026

Votes to approve minutes: 9, Disapprove: 0, Abstain: 0

2 New Business

This meeting of the IBC is open to the public pursuant to the NIH Guidelines, Section IV-B-2-a-(6).

- A replacement US Government policy for Dual Use Research of Concern (or "Dangerous Gain of Function") is expected any day.
- Our next meeting is scheduled for Friday, August 7th.
- Member issues
 - None reported.

3 Reportable Incidents

- No reportable incidents occurred this month.
- A needlestick was reported associated with (non-recombinant) HIV work in rodents. A safety stand-down was initiated by the IBC Chair, IBC Institutional Official, and Executive Director of EHS to ensure procedures and precautions are appropriate moving forward.

4 New IBC Submission

Short Title: Regulation of canonical and non-canonical substrates of histone lysine methyltransferases

Investigator: Jia-Ray Yu

ID: IBC-00008935

Analyst: John O'Neill

VA-Related: No

Discussion: This protocol involves the use of lentivirus in human and murine cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a using BSL-2 facilities and practices with sharps precautions. This protocol also involves the use of baculovirus in insect cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-E-1 using BSL-1 facilities and practices. Finally, this protocol involves the use of plasmids and CRISPR/Cas9 technology in human and murine cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-F-8 Appendix C-1 using BSL-2 facilities and practices. The following modifications are required to secure approval: 1) Complete the training, qualifications, and procedures sections for the PI; 2) Add new laboratory staff; and 3) Add the bacterial selection marker for the lentiviral vector and plasmid.

Motion: RMSA

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

5 Modification Discussions

Short Title: Investigation of SARS-CoV-2 and related coronaviruses

Investigator: Matthew Frieman

ID: IBC-00005484

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of lentivirus in human and murine cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a using BSL-2 facilities and practices with sharps precautions. This modification also involves the use of a BAC containing MHV-A59 in *E. coli*, *S. cerevisiae*, human cells, monkey cells, and mouse cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-2-a (updated to III-D-3-a) using BSL-2 facilities and practices. The following modifications are required to secure approval: 1) Change the NIH Guideline for the new construct to III-D-3-a; 2) Fix the typo in MHV-A59; 3) Move the statement for MHV-A59 from "Animal Data" to "Pathogenicity"; 4) Remove outdated documents; and 5) Update the attached SOP to the 2026 version.

Motion: RMSA

Vote: For: 8, Against: 0, Abstained: 0, Recused: 1 (Matthew Frieman)

Short Title: Immunopathogenesis of Infectious Diseases

Investigator: Joao Pedra

ID: IBC-00002247

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of non-recombinant *Borrelia spp.* in animals using ABSL-2 practices and ABSL-1 facilities. The committee was asked to review the risk assessment associated with the ABSL-1 facility. The following modifications are required to secure approval: 1) Update IACUC information and 2) Describe biosecurity procedures for hypothetical animal escape.

Motion: RMSA

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Genetic studies of hearing and vision impairment

Investigator: Saima Riazuddin

ID: IBC-00002828

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of CRISPR/Cas9 technology to create transgenic animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a using ABSL-1 facilities and practices. This modification also involves the use of mRNA in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-F-1 using ABSL-1 facilities and practices. The following modifications are required to secure approval: 1) Update IACUC information and 2) Clarify the genes of interest for the morpholino, CRISPR/Cas9, and mRNA entries.

Motion: RMSA

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Translational Laboratory Shared Service (TLSS)

Investigator: Rena Lapidus

ID: IBC-00001298

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of previously transduced cells in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a using ABSL-2 facilities and practices. The following modification is required to secure approval: Add updated language for lentivirus post-exposure prophylaxis.

Motion: RMSA

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Automated Stem Cell Radiolabeling via 3D Microprinting-Enabled Microfluidics

Investigator: Mirosław Janowski

ID: IBC-00005346

Analyst: Holda Ramos

VA-Related: Yes

Discussion: This modification involves the use of mRNA and plasmids in animals and mammalian cells. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-b using ABSL-1 facilities and practices. The following modifications are required to secure approval: 1) Reconcile the personnel list with the associated animal protocol and 2) Update IACUC information.

Motion: RMSA

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Epigenetic regulation in prostate cancer progression and therapeutic resistance of prostate cancer

Investigator: Jianfei Qi

ID: IBC-00002354

Analyst: Holda Ramos

VA-Related: No

Discussion: This modification involves the use of lentivirus in cells which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2/ABSL-2 facilities and practices with sharps precautions.

Motion: Approve the Modification

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: STRUCTURAL AND FUNCTIONAL INVESTIGATIONS OF PROTEINS AND COMPLEXES

Investigator: Syed Saif Hasan

ID: IBC-00004974

Analyst: Holda Ramos

VA-Related: No

Discussion: This modification involves the generation of recombinant MHV-A59 in mammalian cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-3-a using BSL-2 facilities and practices. The following modifications are required to secure approval: 1) Move safety information from the experimental design to the risk assessment pages. 2) Update virus risk group.

Motion: RMSA

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Molecular and Functional Studies of Depression and Addiction on Brain

Investigator: Mary Kay Lobo

ID: IBC-00001687

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a using ABSL-1 facilities and practices. The following modifications are required to secure

approval: 1) Update IACUC information; 2) Save and upload a copy of the current Experimental Design; and 3) Write a new Experimental Design that focuses on the current aims of the laboratory.

Motion: RMSA

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Development and preclinical evaluation of novel therapeutic delivery strategies

Investigator: Jung Soo Suk

ID: IBC-00007510

Analyst: Holda Ramos

VA-Related: No

Discussion: This modification involves the use of plasmids, mRNA, and sgRNA in animals and mammalian cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.

Motion: Approve the Modification

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Adeno-associated viral (AAV) gene insertion to manipulate neural activity during drug craving and social behaviors

Investigator: Marco Venniro

ID: IBC-00006148

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.

Motion: Approve the Modification

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Mechanisms of fate determination in peripheral T cells

Investigator: Nevil Singh

ID: IBC-00002339

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of an MSCV vector in human and murine cells which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2 facilities and practices.

Motion: Approve the Modification

Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Role of Cacna1c in mood disorder related behaviors in the mouse using AAV Cre to delete Cacna1c in Floxed Cacna1c mice.
Investigator: Todd Gould
ID: IBC-00002171
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of AAV constructs in animals. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-a and is approved using ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Assessment of sleep regulating cells in preoptic brain regions
Investigator: Jessica Mong
ID: IBC-00005329
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

6 RMSA Follow-Up

Short Title: Role of Immune system on Tumor antigens
Investigator: Anirban Banerjee
ID: IBC-00005821
Analyst: John O'Neill
VA-Related: Yes
Discussion: This modification involves the use of previously transduced human and murine cells in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using ABSL-2 facilities and practices for work with human cells and ABSL-1 facilities and practices for work with murine cells. This modification also involves the use of lentivirus in human cells in vitro. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2 facilities and practices with sharps precautions. The following modification was made to secure approval: Added "eosinophils" to the cell list in table entry ID23056 on the Recombinant DNA Questions page.
Status: Approved

Short Title: Virus construct use in mouse

Investigator: Adam Puche
ID: IBC-00001487
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the use of AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices. The following modifications were made to secure approval: 1) Updated personnel and 2) Updated IACUC information.
Status: Approved

Short Title: Translation Rewiring Underlines Drug Resistance to Lethal Targeted Ribosome Biogenesis Therapeutics in Cancer
Investigator: Wenjun Fan
ID: IBC-00008839
Analyst: Holda Ramos
VA-Related: No
Discussion: This protocol involves the use of plasmids and CRISPR technology in mammalian cells which will be used in animals. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-b and is approved using BSL-2 and ABSL-2 facilities and practices. The following modifications were made to secure approval: 1) Included IACUC information, 2) Added origin of Cas9 gene expressed, 3) Clarified cell lines that will be used, 4) Updated the NIH guidelines the work is applicable to, and 5) Updated the word "standard" in the risk assessment to "BSL-2."
Status: Approved

7 Safety Stand-Down

Short Title: Long-term Inhibition of HIV transcription by targeting cellular CDK9 in vivo
Investigator: Alonso Heredia
ID: IBC-00003501
VA-Related: No
Discussion: Work on this protocol was halted for a safety stand-down while injury procedures and related personnel training were reviewed.

8 Periodic Reviews of Protocols with Recombinant or Synthetic Nucleic Acid Moledules

Short Title: In vitro gene deletion using adenoviral vectors
Investigator: Ryan Riddle
ID: IBC-00006677
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Understanding the molecular mechanisms driving pulmonary fibrosis

Investigator: Konstantin Tsoyi
ID: IBC-00008472
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: Age de-escalation safety trial of PfSPZ-LARC2 Vaccine in Burkina Faso (HP-00107768)
Investigator: Matthew Laurens
ID: IBC-00007529
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Gene transfer in mouse hindlimb ischemia.
Investigator: Rajabrata Sarkar
ID: IBC-00000618
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Effects of early alcohol exposure on brain development
Investigator: Alexandre Medina de Jesus
ID: IBC-00001979
Analyst: John O'Neill
VA-Related: Yes
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2339GCCC: Ph I/IIa of BNT142 in patients with CLDN6-positive advanced solid tumors
Investigator: Heather Mannuel
ID: IBC-00007420
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: LDL receptor family members and their role in Atherosclerosis and Vascular Biology
Investigator: Dudley Strickland
ID: IBC-00004501
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Effect of gene transfer of anti thrombotic factors on the formation and resolution in mouse inferior vena cava (IVC) thrombus
Investigator: Rajabrata Sarkar

ID: IBC-00000993
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2005GCCC: A PHASE 2, OPEN-LABEL, TRIAL OF JCAR017 IN R/R INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
Investigator: Aaron Rapoport
ID: IBC-00005480
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Xenotransplantation of genetically engineered porcine kidneys and livers in baboons
Investigator: Raphael Meier
ID: IBC-00008213
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Transgenic mice for research of maternal diabetes-induced birth defects
Investigator: Peixin Yang
ID: IBC-00006928
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Pathogenesis of Muscular Dystrophies
Investigator: Robert Bloch
ID: IBC-00000188
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Maintenance of transgenic and wild type zebrafish for molecular endocrinology and developmental biology studies.
Investigator: Yonathan Zohar
ID: IBC-00002423
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Roles of androgen receptor and sex specific transcription factors in cannabinoid and opioid receptor regulation
Investigator: Jin Ro
ID: IBC-00002474

Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Epigenetic regulation in prostate cancer progression and therapeutic resistance of prostate cancer
Investigator: Jianfei Qi
ID: IBC-00002354
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2487GCCC: Anitocabtagene Autoleucel vs. Standard of Care Therapy in Participants With Relapsed/Refractory MM
Investigator: Mehmet Kocoglu
ID: IBC-00008056
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Tissue regeneration and cell signaling in muskeloskeletal system
Investigator: Jie Jiang
ID: IBC-00004800
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Reprograming stem cells for muscle repair
Investigator: Shaojun Du
ID: IBC-00001891
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Develop a DNA based vaccine for Mycobacterium marinum in fish
Investigator: Nili Zmora
ID: IBC-00008482
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Pathogenesis of Muscular Dystrophies
Investigator: Robert Bloch
ID: IBC-00000188
Analyst: Holda Ramos
VA-Related: No

Discussion: There have been no substantive changes to this protocol submission.

Short Title: Epigenetic and molecular signatures specific to transplantation and ex vivo perfusion
Investigator: Valeria Mas
ID: IBC-00005933
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Testing and Application of Novel Probiotic Bacteria for use in Marine Aquaculture
Investigator: Harold Schreier
ID: IBC-00003522
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Protein-Protein Interactions in Striated Muscle
Investigator: Robert Bloch
ID: IBC-00000754
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Role of mesenchymal stem cells in neural injury and pain control
Investigator: Ke Ren
ID: IBC-00000390
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2290GCCC: Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Investigator: Jean Yared
ID: IBC-00007149
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Engineering adenoviral vectors as vaccines for infectious disease
Investigator: Lynda Coughlan
ID: IBC-00005922
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for the use of discarded human material in previously approved experiments.

Short Title: Long-term Inhibition of HIV transcription by targeting cellular CDK9 in vivo
Investigator: Alonso Heredia
ID: IBC-00003501
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Interrogating the roles of sarcomeric proteins Obscurin and Myosin-Binding Protein C, slow skeletal isoform in cardiac and skeletal myopathies
Investigator: Aikaterini Kontrogianni-Konstantopoulos
ID: IBC-00007262
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantives changes to this protocol submission.

Short Title: Genome Engineering Core
Investigator: Rena Lapidus
ID: IBC-00004427
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Signal Nodal Targeting in Defined Models of Human Prostate Cancer
Investigator: Arif Hussain
ID: IBC-00007207
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Protein-Protein Interactions in Striated Muscle
Investigator: Robert Bloch
ID: IBC-00000754
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Screening of BSL2 viruses with anti-viral compounds
Investigator: Matthew Frieman
ID: IBC-00002948
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of plasmids *in vitro*. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-F-8 Appendix C and has been administratively approved using BSL-2 facilities and practices.

Short Title: Development and evaluation of novel nanotherapies for glioblastoma in clinically relevant animal models
Investigator: Graeme Woodworth
ID: IBC-00002350
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel, updates of lab and biosafety cabinet location.

Short Title: Lab assays to measure immune responses to pathogens and vaccines
Investigator: Marcela Pasetti
ID: IBC-00003017
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Regulatory processes of voltage gated calcium channels
Investigator: Ivy Dick
ID: IBC-00003852
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Immunopathogenesis of Infectious Diseases
Investigator: Joao Pedra
ID: IBC-00002247
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Long-term Inhibition of HIV transcription by targeting cellular CDK9 in vivo
Investigator: Alonso Heredia
ID: IBC-00003501
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Cytoskeletal proteins in striated muscle pathophysiology
Investigator: Aikaterini Kontrogianni-Konstantopoulos
ID: IBC-00000466
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the use of previously transduced cells *in vitro*. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-F-8 appendix C and is administratively approved using BSL-2 facilities and practices.

Short Title:	Genomic specification of heme in nutrition and development
Investigator:	Iqbal Hamza
ID:	IBC-00006944
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification has been administratively approved for changes in personnel.

Short Title:	Novel mechanisms and interventions of vascular remodeling in lung injury
Investigator:	Kelly Schweitzer
ID:	IBC-00008530
Analyst:	Holda Ramos
VA-Related:	No
Discussion:	This modification has been administratively approved for changes in personnel.

Short Title:	Virotherapy for vaccine and oncology applications
Investigator:	Bolni Nagalo
ID:	IBC-00008432
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification has been administratively approved for changes in personnel.

Short Title:	Engineering adenoviral vectors as vaccines for infectious disease
Investigator:	Lynda Coughlan
ID:	IBC-00005922
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification has been administratively approved for updating the biosafety cabinet certification dates.
